Drug intelligence / Profile preview

GDA-201 + rituximab

Development stage: Unknown
Lead developer: Gamida Cell
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Subcutaneous (IL-2 Used Adjunctively)

Overview

GDA-201 + rituximab is an investigational combination therapy comprising GDA-201, a metabolically enhanced, ex vivo expanded allogeneic natural killer (NK) cell product, and rituximab, a monoclonal antibody targeting CD20. GDA-201 is manufactured from donor peripheral blood mononuclear cells, CD3-depleted and expanded with nicotinamide (NAM) and interleukin-15 (IL-15), which enhances NK cell proliferation, organ trafficking, and resistance to exhaustion. Rituximab mediates B cell depletion through targeting CD20-positive B cells via antibody-dependent cell-mediated cytotoxicity (ADCC). The combination is designed for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), particularly B cell lymphomas. The immunotherapy leverages enhanced NK cell activity and targeted monoclonal antibody therapy to achieve durable complete and partial remissions.

Other names: GDA-201 + rituximab

Targets

CD20 (B-lymphocyte antigen CD20)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on GDA-201 + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDA-201 + rituximab.

Explore the full profile